Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Joel Michalski (NPI 1437599248)

Field	Value
Entity Type	Individual
Organization	Joel Michalski
Address	982055 Nebraska Medical Ctr
City	Omaha
State	NE
ZIP	68198
Taxonomy	Internal Medicine Physician
NPI Enumerated	June 26, 2013

Payer Source	Total Paid
Medicare	$2M
Medicaid	$0

Key Findings

This provider’s billing is effectively single‑payer: total Medicare revenue is $2M and there is no Medicaid billing on file, which indicates Medicare dominates the practice’s payer mix and leaves little Medicaid-driven revenue diversification. Analysts should treat Medicare reimbursement policy and drug payment changes as the primary financial levers for this entity.

Revenue is highly concentrated in a handful of high-cost drug codes: the precomputed top 3 Medicare codes account for 75.2% of this provider’s total Medicare revenue, driven by J9271 ($799.9K, 40.7%), J9144 ($458.3K, 23.3%), and J1569 ($220.3K, 11.2%). This concentration implies the bulk of income depends on a small set of biologic/oncology products rather than routine office-based services.

The mix of codes indicates an infusion- and specialty-drug–focused operation: J9271 (pembrolizumab) and J9144 (daratumumab) are oncology biologics and J1569 is immune globulin, while chemotherapy/infusion administration codes such as 96413 (427 claims, $39.7K, 2.0%), 96365 (221 claims, $10.2K, 0.5%), and G0498 (77 claims, $8.9K, 0.5%) show supporting infusion services. Together these entries are consistent with an outpatient infusion/oncology treatment pattern within an internal medicine taxonomy rather than a predominantly clinic-based primary care mix.

On competitive standing for the top drugs, volumes are above median but not dominant nationally: J9271 ranks #478 of 1841 (74th percentile, typical), J9144 ranks #147 of 615 (75th percentile, typical), and J1569 ranks #130 of 542 (76th percentile, typical). In plain terms, the provider is a meaningful regional participant in these specialty drug administrations but not a top national outlier for those medications.

One notable statistical outlier is evaluation-and-management code 99214 (1.2K claims, $104.4K, 5.3%), which ranks #7591 of 479517 providers nationally (98th percentile; extreme outlier). That high E/M volume relative to peers suggests a substantial number of established-patient visits, which may reflect follow-up care associated with ongoing infusion regimens or a sizable established patient panel.

The provider has an established enrollment history (NPI enumerated 2013-06-26 (~13 years ago)) and practices as an Internal Medicine Physician in Omaha, NE, indicating a multi-year operating presence in the market. Tenure of ~13 years supports the interpretation that the current specialty-infused mix is a developed practice pattern rather than a recent experiment.

There is evidence of exposure to biosimilars and alternative biologic suppliers: Q5123 (rituximab-arrx biosimilar) appears with $61.3K revenue (3.1%) and ranks #26 of 40 providers nationally (36th percentile), indicating some use of biosimilar products in the regimen mix. Payers and competitors should note this as a potential lever for margin pressure or cost-savings negotiations, since substitution or larger-scale biosimilar adoption could shift revenue per claim dynamics.

From an operational risk perspective, reliance on a small set of expensive injectable drugs (top 3 = 75.2% of Medicare revenue) combined with no Medicaid billing magnifies sensitivity to Medicare drug reimbursement changes, prior authorization policies, and shifts toward in-office infusion consolidation or site-of-care migration. For contracting and network decisions, this profile flags both concentration risk and a clear strategic focus on infusion-based specialty therapy delivery.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

68 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	18,600	$40	$799.9K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	12,060	$40	$458.3K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	6,120	$40	$220.3K
J0897	Injection, denosumab, 1 mg	6,000	$20	$114K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,170	$90	$104.4K
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	1,750	$40	$61.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	430	$90	$39.7K
J1439	Injection, ferric carboxymaltose, 1 mg	26,250	$1	$26.3K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	11,900	$1	$23.8K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	130	$130	$16.1K

Showing 1–10 of 68

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 68 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Joel Michalski — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

68 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	7	30	14,400	$40	$671.6K
J9144	4	10	10,440	$40	$434.6K
J1569	3	10	5,980	$40	$224.3K
Q5123	2	10	2,430	$30	$83.5K
J0897	30	200	2,040	$20	$62.7K
J0881	10	10	17,260	$1	$54.5K
J1439	15	30	25,880	$1	$26.4K
J9217	54	50	110	$130	$20.6K
96413	13	80	60	$90	$18.2K
99214	50	3,210	110	$70	$14.9K

Showing 1–10 of 68

Related Providers

Other providers that share a Tax Identification Number (TIN) with Joel Michalski, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Stefano Tarantolo	NE	Hematology & Oncology Physician	$3.2M	$0
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Ralph Hauke	NE	Hematology & Oncology Physician	$2.5M	$0
Gamini Sooriyaarachchi	FL	Medical Oncology Physician	$2.2M	$0
Ryan Ramaekers	NE	Hematology & Oncology Physician	$2.1M	$0
Yungpo Su	NE	Hematology & Oncology Physician	$1.9M	$0
Margaret Block	NE	Hematology & Oncology Physician	$1.7M	$0
Robert Langdon	NE	Hematology & Oncology Physician	$1.4M	$0
Muhammad Haroon	NE	Hematology & Oncology Physician	$1.4M	$0
Think Aksarben, LLC	NE	Multi-Specialty Clinic/Center	$0	$1.2M

Nearby Providers

Other providers in the same ZIP code as Joel Michalski, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The Nebraska Medical Center	NE	General Acute Care Hospital	$0	$76.5M
Unmc Physicians	NE	Multi-Specialty Clinic/Center	$0	$41.1M
David Crockett	NE	Internal Medicine Physician	$982.8K	$0
Unmc College Of Dentistry	NE	Dentist	$0	$974.6K
Amanda Dimmitt	NE	Diagnostic Radiology Physician	$287.6K	$0
Joel Brink	NE	Diagnostic Radiology Physician	$285.8K	$0
Han Kim	NE	General Practice Dentistry	$0	$285.8K
Shahid Hussain	NE	Diagnostic Radiology Physician	$201.7K	$32.5K
Brent Timperley	NE	Ophthalmology Physician	$204.9K	$0
Chris Cornett	NE	Orthopaedic Surgery Physician	$203K	$0

Joel Michalski — Billing Profile & Reimbursement Data

Sign up for Joel Michalski — Billing Profile & Reimbursement Data policy alerts

Joel Michalski — Billing Profile & Reimbursement Data

Sign up for Joel Michalski — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References